BTK and B-cell chronic lymphocytic leukemia: Specifically, C481S, C481F, C481Y, T316A, T474I, and T474S mutate of BTK could be affected by ibrutinib to improve the prognosis of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.